Insights - Revance Therapeutics’ (RVNC) cervical dystonia results were released after the bell on Monday. The phase 2 trial was an open-label dose-ranging study to evaluate the … Continue Reading
Premium: Read NowInsights - Biotech stocks are getting shellacked today due to a Trump comment in Time’s “Person of the Year” edition. It’s quite literally a single comment on … Continue Reading
Read NowInsights - Cerecor (CERC) announced the failure of a phase 2 study of CERC-501, its kappa opioid receptor (KOR) antagonist, yesterday morning, sending the stock down by … Continue Reading
Read NowInsights - CAR-T candidates are again stealing the spotlight at ASH this year, though for entirely different reasons than in the past. First, Juno’s (JUNO) safety issues … Continue Reading
Premium: Read NowInsights - A reminder that the American Society of Hematology annual meeting gets started tomorrow and runs through Tuesday. The smaller San Antonio Breast Cancer Symposium follows … Continue Reading
Premium: Read NowInsights - Donald Trump has been elected the 45th president of the United States! Between the Trump victory, Republicans maintaining congress, and the failure of California’s Proposition … Continue Reading
Read NowInsights - In last week’s webinar, we discussed why the Presidential election has been weighing on the sector. It’s not just a Clinton Victory (which is largely … Continue Reading
Premium: Read Now
